What is PHAT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.48B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PHAT?

P/E (TTM) is n/a and 52-week range is $5.01 to $18.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PHAT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PHAT?

The company profile lists revenue (TTM) near $233M, net income (TTM) near -$9.62B, EPS (TTM) near -$1.27 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Phathom Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Florham Park, New Jersey, US, 81.3M shares outstanding, ISIN US71722W1071 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Phathom Pharmaceuticals, Inc.

$PHAT

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 371 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the commercialization and development of novel treatments for gastrointestinal diseases. The company has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The firm markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Employees

371

Website

www.phathompharma.com/

IPO

2019-10-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US71722W1071

Headquarters

Florham Park, New Jersey, US

Shares outstanding

81.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

75.71%

Browse other companiesFree AI scores and summaries for more stocks